# Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isopropyl

> **NCT05279716** · PHASE4 · UNKNOWN · sponsor: **Santen Pharmaceutical Asia Pte. Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Normal Tension Glaucoma
- Primary Open-angle Glaucoma
- Glaucoma, Suspect
- Ocular Hypertension

## Interventions

- **DRUG:** Eybelis ophthalmic solution 0.002%

## Key facts

- **NCT ID:** NCT05279716
- **Lead sponsor:** Santen Pharmaceutical Asia Pte. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-15
- **Primary completion:** 2022-12-08
- **Final completion:** 2023-11-20
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2022-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05279716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05279716, "Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isopropyl". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05279716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*